SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. ___)*
Arena Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $.0001 per share
(Title of Class of Stock)
040047 10 2
(CUSIP Number)
July 28, 2000
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant
to which this Schedule is filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[X] Rule 13d-1(d)
*The remainder of this cover page shall be filled out
for a reporting person's initial filing on this form with respect
to the subject class of securities, and for any subsequent
amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover
page shall not be deemed to be "filed" for the purpose of Section
18 of the Securities Exchange Act of 1934 ("Act") or otherwise
subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see
the Notes).
SCHEDULE 13G
CUSIP No.
040047 10 2
_____________________________________________________________
1 NAMES OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
TRIPOS, INC.
43-1454986
_____________________________________________________________
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
_____________________________________________________________
3 SEC USE ONLY
_____________________________________________________________
4 CITIZENSHIP OR PLACE OF ORGANIZATION
UTAH
_____________________________________________________________
5 SOLE VOTING POWER NUMBER OF SHARES
2,015,840
_____________________________________________________________
6 SHARED VOTING POWER BENEFICIALLY OWNED BY
None
_____________________________________________________________
7 SOLE DISPOSITIVE POWER EACH REPORTING
2,015,840
_____________________________________________________________
8 SHARED DISPOSITIVE POWER PERSON WITH
None
_____________________________________________________________
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,015,840
_____________________________________________________________
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* [ ]
_____________________________________________________________
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.3%
_____________________________________________________________
12 TYPE OF REPORTING PERSON*
CO
_____________________________________________________________
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Item 1(a) Name of Issuer:
Arena Pharmaceuticals, Inc.
Item 1(b) Address of Issuer's Principal Executive Offices:
6166 Nancy Ridge Drive
San Diego, CA 92121
Item 2(a) Name of Person Filing:
Tripos, Inc.
Item 2(b) Address of Principal Business Office
1699 South Hanley Road
St. Louis, MO 63144
Item 2(c) Citizenship:
Tripos, Inc. is a Utah corporation with its
principal offices in Missouri
Item 2(d) Title of Class of Securities:
Common Stock, par value $.0001 per share
Item 2(e) CUSIP Number:
040047 10 2
Item 3. If this statement is filed pursuant to 240.13d-
1(b) or 240.13d-2(b) or (c), check whether the
person filing is a:
(a) [ ] Broker or dealer registered under section 15 of
the Act (15 U.S.C. 78o).
(b) [ ] Bank as defined in section 3(a)(6) of the Act
(15 U.S.C. 78c).
(c) [ ] Insurance company as defined in section
3(a)(19)of the Act (15 U.S.C. 78c).
(d) [ ] Investment company registered under section 8
of the Investment Company Act of 1940 (15 U.S.C.
80a-8)
(e) [ ] An investment adviser in accordance
with 240.13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in
accordance with 240.13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in
accordance with 240.13d-1(b)(1)(ii)(G);
(h) [ ] A savings association as defined in Section
3(b) of the Federal Deposit Insurance Act (12
U.S.C. 1813);
(i) [ ] A church plan that is excluded from the
definition of an investment company under section
3(c)(14) of the Investment Company Act of 1940 (15
U.S.C. 80a-3);
(j) [ ] Group, in accordance with 240.13d
(b)(1)(ii)(J).
If this statement is filed pursuant to 240.13d-1(c), check
this box. [ ]
Item 4. Ownership:
Amount Beneficially Owned: 2,015,840
Percent of Class: 9.3%
Number of shares as to such persons has:
(i) sole power to vote or to direct the vote: 2,015,840
(ii) shared power to vote or to direct the vote: none
(iii)sole power to dispose or to direct the disposition
of:2,015,840
(iv) shared power to dispose or to direct the
disposition of: none
Item 5. Ownership of Five Percent or Less of a Class:
Not applicable
Item 6. Ownership of More Than Five Percent on Behalf of Another
Person:
Not applicable
Item 7. Identification and Classification of the Subsidiary
Which Acquired the Security Being Reported on by the Parent
Holding Company:
Not applicable
Item 8. Identification and Classification of Member of the
Group:
Not applicable
Item 9. Notice of Dissolution of Group:
Not applicable
Item 10. Certification:
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the
effect of changing or influencing the control of the issuer
of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having
such purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge
and belief, I certify that the information set forth in this
statement is true, complete and correct.
Dated August 8, 2000
TRIPOS, INC.
By: /s/ John P. McAlister /s/ Colleen A. Martin
Chief Executive Officer Chief Financial Officer
Attention: Intentional misstatements or omissions of fact
constitute Federal criminal violations. (See 18 U.S.C. 1001)
